PDCD1 and neoplasm: By inhibiting the ligand–receptor interaction of PD-1/PD-L1, it is possible to prevent the activation of the PD-1/PD-L1 signaling pathway, reversing T cell fatigue and preventing immunological responses in the tumor microenvironment (Figure 6) [120].